Namenda neuropathic pain trial
Executive Summary
Forest will initiate a new Phase II trial of Namenda (memantine) for neuropathic pain, with a possible NDA submission by 2006. A previous Phase III study failed to show overall statistical significance in primary endpoint of nocturnal pain, although there was improvement in weekly assessments. Namenda was approved for treatment of moderate to severe Alzheimer's disease Oct. 16 (1"The Pink Sheet" Oct. 20, 2003, p. 3)...